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Available online 16 June 2016Frontotemporal dementia (FTD) is an early onset neurodegenerative disease. Mutations in several genes cause
familial FTD and one of them is charged multivesicular body protein 2B (CHMP2B) on chromosome 3 (FTD3), a
component of the endosomal sorting complex required for transport III (ESCRT-III). We have generated an in-
duced pluripotent stem cell (iPSC) line of a healthy individual and inserted the CHMP2B IVS5AS G-C gene muta-
tion into both alleles, resulting in aberrant splicing. This human iPSC line provides an ideal model to study
CHMP2B-dependent phenotypes of FTD3.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Skin biopsy was obtained from a 63-year-old man (anonymized as
H256) and an induced pluripotent stem cell (iPSC) line, H256 clone
(C) 6, was generated using an episomal vector system carrying tran-
scripts for human OCT4, SOX2, KLF4, L-MYC, LIN28, and small hairpin
RNA for TP53 (Okita et al., 2011; Rasmussen et al., 2014).
We then generated a homozygous CHMP2B point-mutation (patho-
genic G-to-C transition in the 5′ acceptor splice site of exon 6) in this
iPSC line via the CRISPR-Cas9 system (Ran et al., 2013). The mutation
was validated by DNA sequencing (Fig. 1A).
Subsequently, we conﬁrmed that the gene modiﬁed clone of H256
C6, termed CHMP2B IVS5AS GG-CC, remained truly pluripotent. This
was demonstrated via expression analyses of key pluripotency markers
on protein level (Fig. 1B). Additionally, CHMP2B IVS5AS GG-CC retained
the potential to differentiate into cell types of all three germ layers upon
embryoid body formation (Fig. 1C). More importantly, the gene editing
process introduced no genetic chromosomal aberrations and the cells
exhibit a normal karyotype (Fig. 1D).
In summary, we have generated a disease-speciﬁc homozygous
CHMP2B mutant human iPSC line. Together with one more heterozy-
gous CHMP2Bmutant iPSC line (Zhang et al., submitted to Stem Cell Re-
search) and the original isogenic healthy control, they will serve as an(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Site-speciﬁc introduction of a homozygous mutation in CHMP2B. CHMP2B IVS5AS GG-CC is a bona ﬁde human iPSC line with a normal karyotype. (A) DNA sequencing of both
CHMP2B alleles shows a G-to-C transition in the 5′ acceptor splice site of exon 6 in one allele, using the CRISPR-Cas9 system. (B) OCT4, NANOG, SSEA4, TRA-1-60 and TRA-1-81
immunoﬂuorescence images of CHMP2B IVS5AS GG-CC counterstained with DAPI. Scale bars, 200 μm. (C) Immunocytochemistry for marker proteins representative of the three germ
layers, βIII-TUBULIN (ectoderm), SMA (mesoderm), and AFP (endoderm), after in vitro differentiation of CHMP2B IVS5AS GG-CC by embryoid body formation. Scale bars, 200 μm. (F)
Chromosome analysis of CHMP2B IVS5AS GG-CC showing a normal 46, XY karyotype.
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FTD3 (Skibinski et al., 2005), independent of the familial background
and thereby completely focused on the biological effect of the particular
CHMP2B mutation.
Materials and methods
CRISPR design
CHMP2B IVS5AS GG-CCwas obtained using the CRISPR-Cas9 system
in combination with ssODNs serving, as homologous templates cover-
ing the site were the mutation was integrated. CRISPRs were designed
at http://crispr.mit.edu/. The CRISPRswere generated following the pro-
tocol from Ran et al. (Ran et al., 2013) in a single plasmid containing
both sgRNA and the Cas9 (pSpCas9(BB)-2A-Puro (PX459) V2.0 was a
gift from Feng Zhang (Addgene plasmid # 62988)).
Transfection
iPSCs maintained on matrigel coated dishes (Corning Bioscience) in
E8medium (Gibco)were detached using Accutase (Gibco). 2 × 106 cells
were co-transfected with 10 μg of the CRISPR-Cas9 plasmid (Addgene,
62,988) and 1 μL of the ssODNs.We used a 4Dnucleofector (programme
CA167) from Amaxa in combination with the P3 Primary Cell Kit for
transfection. iPSCs were subsequently transferred back to a matrigel-
coated dish in E8 medium supplemented with 1 mM ROCK inhibitor
(Sigma). 24 h post-transfection, cells were subjected to puromycin se-
lection for 48 h and allowed to recover for a week. Resistant colonies
were picked and expanded for genotyping.
Genotyping
DNA for genotypingwas extracted using the prepGEM™ kit (zyGEM,
PTI0500). PCR genotypingwas performed using TEMPase Hot Start DNA
Polymerase (Ampliqon) according to themanufacturer's instructions at
an annealing temperature of 58 °C. The following primers were de-
signed 444 base pairs upstream and 162 base pairs downstream of the
CRISPR cutting site to detect successful gene editing: CHMP2B forward
5′-TGTTCACTGAGTTTGCCTTCTG-3′ and CHMP2B reverse 5′-
ACCAAGCACAGTGCAGATTTC-3′. Clones in which both wildtype alleles
were successfully replacedwith the CHMP2Bmutant ssODNswere sub-
jected to sequencing in order to ensure the inserted pointmutation and
exclude introduction of frameshifts or other mutations.
DNA sequencing
Sanger sequencing of a 606 base pair region around the 5′ acceptor
splice site of exon 6 region of the CHMP2B gene was carried out in an
ABI PRISM 310 Genetic Analyzer.
Immunocytochemistry
iPSCs were ﬁxed with 4% paraformaldehyde in DPBS for 15 min and
immunocytochemistry was performed by standard immunoﬂuores-
cence staining procedures. The following primary antibodies were
used: Anti-OCT4 (Santa Cruz, sc-8628); anti-NANOG (Peprotech, 500-
P236); anti-SSEA4 (BioLegend, 330402); anti-TRA-1-60 (BioLegend,
330602); anti-TRA-1-81 (BioLegend, 330702); anti-βIII-TUBULIN
(Millipore, MAB1637); anti-SMA (Dako, M0851), anti-AFP (Dako,A0008); all 1:500. Secondary antibodies used were: Alexa Fluor 488
donkey anti-rabbit (A21207), donkey anti-goat (A11058), and goat
anti-mouse (A11017), all 1:1000 (Molecular Probes).
Embryoid body differentiation
Embryoid body (EB) formation was performed by transferring
EDTA-treated iPSCs to low attachment plates (Corning, NY, USA) in E8.
After 2 days of culture, themediumwas changed toDMEM/F12 contain-
ing 20% knockout serum replacement (Life Technologies), 1× non-es-
sential amino acids, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol
and 1% PenStrep. After 7 days, the EBs were plated on 0.5 μg/cm2
vitronectin (Life Technologies) coated dishes and cultured in DMEM
supplemented with 10% FBS, 2 mM L-glutamine and 1% Pen/Strep for
ecto-, meso- and endoderm induction up to three weeks. Subsequently,
EBs were ﬁxed for 15 min in 4% PFA for immunocytochemistry.
Karyotyping
iPSCs were treated for 45 min with KaryoMAX colcemid (Life Tech-
nologies), harvested in fresh ﬁxative consisting of 25% acetic acid and
75%methanol and sent for G-band karyotyping (Cell Guidance Systems,
UK).
Veriﬁcation and authentication
Karyotyping was performed by Cell Guidance Systems (UK) and a
minimumof 20metaphaseswas analyzed. The results showed a normal
46, XY karyotype, without any detectable abnormalities (Fig. 1D).
CHMP2B IVS5AS GG-CC iPSC line identity and purity was conﬁrmed
by sequencing of CHMP2B (Fig. 1A) and ICC for pluripotency markers
expression (Fig. 1B).
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